BC Week In Review | Jun 11, 2012
Clinical News

HyperAcute Melanoma: Phase II data

Additional data from 16 patients with stage IV melanoma in an open-label, U.S. Phase II trial showed that HyperAcute Melanoma plus PegIntron peginterferon alfa-2b produced 2 complete responses, 2 cases of stable disease and 3...
BioCentury | Nov 7, 2011
Finance

HyperAcute IPO

Cancer vaccine company NewLink Genetics Corp. is hoping to get its IPO out the door this week. The Iowa biotech hopes to sell 5.5 million shares at $10-$12. An $11 price would raise $60.5 million...
BC Week In Review | Jun 13, 2011
Clinical News

HyperAcute Melanoma: Phase II data

An open-label, U.S. Phase II trial in 16 patients with stage IV melanoma showed that HyperAcute Melanoma plus PEG-Intron peginterferon alfa-2b produced 2 complete responses and 1 case of stable disease. The trial also enrolled...
BioCentury | Jan 3, 2011
Finance

Iowa to IPO

Iowa to IPO Cancer vaccine company NewLink Genetics Corp. , founded in 1999 by practicing oncologist and company CEO and CSO Charles Link, has filed to raise up to $86.3 million in an IPO. The Iowa...
BC Innovations | Jan 31, 2008
Cover Story

CD200: A Solid Argument

The two companies developing anti- CD200 antibodies to treat blood cancers- Alexion Pharmaceuticals Inc. and Trillium Therapeutics Inc .-might have had a new indication land in their laps. In a paper published in The Journal...
Items per page:
1 - 5 of 5